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CRISPR and the Future of Fertility Innovation
June Carbone*
In 2018, Dr. He Jiankui announced that he had used CRISPR, a gene-
editing tool, to produce newborn twin girls with the gene for HIV resistance.1
The announcement caused a global uproar. Dr. He appeared to have tried the
procedure without advance testing.2 He did so without assurance the proce-
dure was safe; indeed, unintended side effects could affect not only the twins
but the twins’ own offspring.3 And he did it to otherwise healthy embryos.4
While the twins risked exposure to the HIV virus their father carried, less
risky treatments exist that reduce the risk of transmission.5 Dr. He also tried
the technique without following appropriate Chinese protocols.6 As a result
of the outcry that followed his announcement, use of the procedure in China
has been effectively shut down.7 This leaves open the question: if CRISPR is
to be used again in the reproductive context, how and why is it to occur?
CRISPR creates new possibilities for genetic engineering, which alters a
person’s—or an embryo’s—genetic inheritance in ways that alter the
germline, in turn passing on the alterations to subsequent generations.
CRISPR technology has the potential to save lives, enable prospective par-
* Robina Chair in Law, Science and Technology, University of Minnesota Law
School. I would like to thank Aron Mozes for his research assistance.
1. Mara Hvistendahl, China’s Bioethics Struggles Enter the Spotlight, SLATE
(Nov. 27, 2018, 2:42 PM), https://slate.com/technology/2018/11/he-jiankui-
crispr-babies-informed-consent-china-science.html. Dr. He has a Ph.D., but not
an M.D. This article will refer to him as Dr. He in part to avoid confusion with
the pronoun “he.” For a discussion of his background, see generally Henry T.
Greely, CRISPR’d Babies: Human Germline Genome Editing in the ‘He Ji-
ankui Affair,’ 6 J.L. & BIOSCIENCES 111 (2019).
2. Greely, supra note 1, at 131. Dr. He did claim that he had tried CRISPR on
three hundred embryos, but that claim has not been independently verified.
3. See Rachael Rettner, A Scientist Edited Babies’ Genes in Utero. It Could Make
Them More Likely to Die, LIVESCIENCE (June 3, 2019), https://
www.livescience.com/65620-crispr-babies-gene-mutation-early-death.html (in-
dicating that a study showed that the gene added to confer HIV resistance was
associated with increased risk of early death from other causes, but errors in the
study led it to be withdrawn).
4. Id.
5. Jing-ru Li et al., Experiments that Led to the First Gene-edited Babies: The
Ethical Failings and the Urgent Need for Better Governance, 20 J. ZHEJIANG
U. SCI. B. 32, 35 (2019).
6. Id. at 36. An investigation by the Chinese government reported that Dr. He
conducted the experiments in violation of a Chinese ban on germline editing.
Greely, supra note 1, at 142. In addition, although Dr. He claimed to have
advance approval from the hospital where the procedure was performed, the
validity of that approval is questionable.
7. Greely, supra note 1, at 140.
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ents to reproduce without risk of transmitting unwanted genetic material to
their offspring and, indeed, to eliminate a defective gene from a family line
altogether.8 Yet, the technology is untried and could cause unanticipated
harms.9 This article does not address whether such innovations should occur,
but instead focuses on how they are likely to do so, and whether the develop-
ment of the technology can and should be channeled in particular ways.
This inquiry starts by distinguishing between two different issues that
raise concerns about future use. The first involves safety and efficacy. As
with any other medical techniques, it is impossible to identify every potential
side effect without testing.10 Testing protocols typically involve starting with
animals.11 In the case of human reproduction, the next step would be experi-
mentation on embryos who are not allowed to develop into babies.12 Then, if
those steps look promising, the procedure should be tried on a limited num-
ber of humans, typically humans who might otherwise not exist or would be
born with life threatening illnesses.13 Finally, after human trials that establish
safety and efficacy, the technique might be approved for use in accordance
with appropriate treatment protocols.14 In the context of assisted reproduc-
tion, however, the funding for these steps has typically not been available.15
Congress has banned the expenditure of federal funds on any embryo re-
search, and private commercial donors have been reluctant to fund research
that benefits only a relatively small patient population.16 As a result, most
innovations in assisted reproduction have occurred when fertility profession-
als simply try a new technique on patients, typically without human trials and
sometimes even without extensive animal experimentation.17 CRISPR, on the
other hand, is currently the subject of extensive research, including animal
experimentation, human trials in adults, and some testing in embryos.18 This
testing should lead to refinements and increased confidence in the safety and
8. Kerry Lynn Macintosh, Heritable Genome Editing and the Downsides of a
Global Moratorium, 2 CRISPR J. 272, 272 (2019).
9. See Greely, supra note 1, at 153 (describing potential harms).
10. Id.
11. Id. at 154.
12. For a description of this process, see id. at 128 (observing that the FDA would
require either animal experimentation or in vitro experimentation with embryos
or both before allowing human trials). “In vitro” means in the lab, as opposed
to “in vivo” embryo experiments, which take place in the human body.
13. Id.
14. Id.
15. Greely, supra note 1, at 128.
16. Id. at 129.
17. Id.
18. Id. at 179.
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efficacy of the technique.19 Nonetheless, the issue that cannot be determined
without human trials is the safety of its use in human reproduction and the
ways that it might affect future generations. To test for effects on future gen-
erations requires testing in a patient population and following that population
to see what the effect of the genetic alterations are on the patients’ children.20
It is possible, nonetheless, that CRISPR use could produce otherwise healthy
individuals who are still at risk of transmitting genetic defects to their chil-
dren in ways that researchers cannot effectively anticipate or eliminate.21
Waiting until the safety of the technique is conclusively established would
therefore mean limiting the use of an otherwise promising technique for
decades.
The second issue involves the potential consequences of germline ge-
netic alterations as a general practice. Preventing disease, in and of itself, is
generally regarded as admirable and CRISPR’s primary use could be to de-
lete genes that cause disease.22 The most controversial applications are the
ones that go beyond that.23 For example, some recessive genes, such as those
associated with sickle cell anemia, transmit what could be a devastating ill-
ness in a child who receives two copies of the gene, but have potential advan-
tages in combatting malaria if the child receives only one copy of the gene.24
Genetic engineering that prevented transmission of sickle cell anemia to a
child might therefore be considered a good thing, while elimination of the
genes associated with sickle cell disease from the family line altogether
might have negative consequences. Further, CRISPR may be used not just to
eliminate genes associated with disease but to introduce new genes that the
child would not otherwise have.25 In the case of the Chinese twins, for exam-
ple, Dr. He introduced genes that confer HIV resistance.26 This raises con-
cerns about what some see as a slippery slope. Once CRISPR is used to
introduce new genes associated with advantageous traits, what are the limits
on such use? For example, if CRISPR is used to alter the genes associated
with dwarfism, is there any reason not to introduce a gene associated with
height greater than six feet? Or to offer a package of genes associated with
19. Id.
20. Id. at 114.
21. Greely, supra note 1, at 114.
22. Henry T. Greely, Human Germline Genome Editing: An Assessment, 2
CRISPR J. 253, 257 (2019).
23. Of course, some ethicists and theologians object to all human interventions in
the human genome. These objections go beyond the scope of this article. Id. at
263.
24. Id. at 260.
25. Id. at 263.
26. Hvistendahl, supra note 1.
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choices that may include enhanced memory, fast twitch muscles and greater
sprinting speed, or other traits?27
Looking at how other innovations in assisted reproductive technologies
answered these questions—how innovations have accounted for safety and
efficacy considerations and how new technologies have dealt with the slip-
pery slope of ethically questionable applications—may be instructive in pre-
dicting CRISPR’s likely future. For instance, the development of assisted
reproductive technologies (ARTs) generally, in vitro fertilization (IVF) as the
most critical part of ART, and experimentation with more recent innovations
(such as three parent IVF) offer examples that may be instructive. These
developments suggest that the answers reflect path dependent experiences,
supply and demand pressures, sources of funding, and the contexts in which
the innovations occur.
Applying this framework to the use of CRISPR in assisted reproduction
provides a framework for assessing the likely developments on the horizon.
This analysis suggests that the demand for CRISPR, at least initially, is likely
to be limited and where the demand is small, doctors may be tempted to
simply do it, either in isolated trials or in underground networks. This analy-
sis also suggests that the potentially greater demand requires that CRISPR
use interact with two developing sources of innovation: (1) innovation in-
volving egg freezing and treatment of patients with a limited number of ga-
metes; and (2) innovation addressing the needs of families at risk of passing
on identified genetic defects. These two groups are different from each other
and suggest development of CRISPR along different trajectories.28
This article attempts to consider supply and demand for CRISPR in ac-
cordance with these two different patient populations and to chart the likely
trajectory of the technology in accordance with each, suggesting very differ-
ent outcomes. In accordance with this analysis, this article will, first, consider
the history of innovation in ART.
Second, it will identify the forces remaking reproductive medicine, ar-
guing the industry is experiencing greater consolidation, with pressures for
growth and increased geographic reach. These developments create larger
platforms capable of exploiting jurisdictional differences in price and regula-
tion.29 In addition, the future of fertility treatments is likely to focus much
more intently on the supply of gametes as women seek to reproduce at later
ages.30 These developments may, at least in the short run, focus more atten-
tion on egg freezing, preimplantation genetic diagnoses, and the management
27. For a discussion of ethics of human enhancement, see generally KERRY LYNN
MACINTOSH, ENHANCED BEINGS: HUMAN GERMLINE MODIFICATION AND THE
LAW 11–29 (2018) (discussing prospects to use CRISPR to enhance human
performance).
28. Macintosh, supra note 8, at 274.
29. Greely, supra note 1, at 130.
30. Macintosh, supra note 8, at 274.
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of reproduction in the context of other medical treatments, including genomic
medicine.31
Third, the article explores how human genome editing may occur in the
context of these developments. The article will maintain that the patient pop-
ulation seeking to use genome editing to prevent the transmission of disease
is likely to remain fairly small, but that the demand in the context of other
fertility services may be significantly larger.
The article concludes that thinking about CRISPR use for germline gen-
ome editing requires consideration of the broader forces remaking reproduc-
tive medicine.
I. INNOVATION IN ART: JUST DO IT?
The use of CRISPR in China is not the first controversial use of ART,
nor the first time such technologies have been used to alter the genetic inheri-
tance a new baby may have or may pass onto its offspring.32 Arguably, the
first instance of genetic alteration, that could be passed on to offspring, oc-
curred in New Jersey in the 1990s.33 There, doctors inserted cytoplasm from
donor eggs into the intended mother’s eggs creating embryos that could end
up with DNA from three sources: the intended mother and father whose ga-
metes created the embryo and small amounts of mitochondrial DNA from the
donor.34 Over thirty children were born using the technique, with tests show-
ing that at least two of the children had mitochondrial DNA from the donor.35
The Food and Drug Administration (FDA) asserted jurisdiction over the pro-
cedure, effectively shutting down use of the procedure in the United States.36
31. Id. at 274–75.
32. Jason A. Barritt et al., Epigenetic and Experimental Modifications in Early
Mammalian Development: Part II, Cytoplasmic Transfer in Assisted Reproduc-
tion, 7 HUM. REPROD. UPDATE 428, 428 (2001).
33. Id. at 428–29.
34. See id. at 429 (describing process which involved injection of father’s sperm
and a small amount of cytoplasm from a donor egg into the intended mother’s
egg).
35. Kim Tingley, The Brave New World of Three Parent I.V.F., N.Y. TIMES (June
27, 2014), https://www.nytimes.com/2014/06/29/magazine/the-brave-new-
world-of-three-parent-ivf.html. A subsequent study surveying the parents of
thirteen of the seventeen children reported that the children seemed to be devel-
oping normally.
36. See June Carbone & Jody Lyneé Madeira, Buyers in the Baby Market: Toward
a Transparent Consumerism, 91 WASH. L. REV. 71, 93 (2016) (describing FDA
assertion over jurisdiction); Judith Daar, Multi-Party Parenting in Genetics and
Law: A View from Succession, 49 FAM. L.Q. 71, 74 (2015) (observing that after
the FDA said in 2001 that any further use of cytoplasmic injection would re-
quire an Investigational New Drug application, the practice ceased throughout
the United States); see also Myrisha S. Lewis, How Subterranean Regulation
36 SMU Science and Technology Law Review [Vol. XXIII
In a limited follow-up study that surveyed twelve parents, the children ap-
peared to be developing normally.37 However, given the lack of a control
group and the lack of follow-up testing, it is unclear whether the technique
made the pregnancies possible and how much, if any, of the donor DNA
influenced the children’s development.
The second innovation that can be passed onto offspring involves mito-
chondrial replacement therapy (MRT).38 Mitochondrial DNA mutations can
cause a variety of diseases in children, including devastating neurological
disorders and early death.39 Existing genetic tests cannot screen eggs for mi-
tochondrial disorders because the diseases depend on the distribution and
location of the mutations, which cannot be determined from the single cell
testing used in preimplantation genetic diagnoses (PGD).40 The only way to
Hinders Innovation in Assisted Reproductive Technology, 39 CARDOZO L. REV.
1239, 1256 (2018) (questioning the basis for the FDA’s assertion of jurisdiction
and arguing that the FDA actions have a chilling effect on research). In addi-
tion, in December, 2015, Congress added a rider to the FDA appropriations bill
that prevents the FDA from using federal funds “to notify a sponsor or other-
wise acknowledge receipt of a submission for an exemption for investigational
use of a drug or biological product under Section 505(i) of the Federal Food,
Drug, and Cosmetic Act (21 U.S.C. 355(i)) or Section 351(a)(3) of the Public
Health Service Act (42 U.S.C. 262(a)(3)) in research in which a human embryo
is intentionally created or modified to include a heritable genetic modification.
Any such submission shall be deemed to have not been received by the Secre-
tary, and the exemption may not go into effect.” The Consolidated Appropria-
tions Act of 2016, H.R. 2029, Pub. L. No. 114–113, § 749. See Greely, supra
note 1, at 129 (noting that the rider has been renewed in every appropriations
bill since).
37. See Serena H. Chen et al., A Limited Survey-based Uncontrolled Follow-up
Study of Children Born After Ooplasmic Transplantation in a Single Centre, 33
REPROD. BIOMEDICINE ONLINE 737, 740–42 (2016). Two of the embryos con-
ceived using the technique developed Turner syndrome, a rare chromosomal
abnormality. One of women miscarried and the other aborted the fetus. Tin-
gley, supra note 35. For a discussion of the safety issues, see Kerry L. Macin-
tosh, Brave New Eugenics: Regulating Assisted Reproductive Technologies in
the Name of Better Babies, 2010 U. ILL. J.L. TECH. POL’Y 257, 272 (2010).
38. See Daniel Green, Assessing Parental Rights for Children with Genetic Mate-
rial from Three Parents, 19 MINN. J.L. SCI. & TECH. 251, 255 (2018) (describ-
ing MRT as the transfer of nuclear DNA from intended parents to an egg or
fertilized embryo from a donor, eliminating transmission of the intended
mother’s mitochondrial DNA to the child).
39. Andrew M. Schaefer et al., The Epidemiology of Mitochondrial Disorders—
Past, Present and Future, 1659 BIOCHIMICA ET BIOPHYSICA ACTA 115, 118
(2004).
40. See Amy B. Leiser, Parentage Disputes in the Age of Mitochondrial Replace-
ment Therapy, 104 GEO. L.J. 413, 419 (2016); see also NUFFIELD COUNCIL ON
BIOETHICS, NOVEL TECHNIQUES FOR THE PREVENTION OF MITOCHONDRIAL
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eliminate the transmission of the mother’s potentially defective mitochon-
drial DNA to a fetus therefore, is through MRT.41 MRT involves taking a
donor egg or embryo, removing the nucleus, and inserting nuclear DNA from
the intended parents.42 The resulting embryo would then contain the nuclear
DNA from the intended parents and the mitochondrial DNA from the do-
nors.43 Since mitochondrial DNA is passed to offspring only through the
mother’s egg cells, women, but not men, would then pass on the donor mito-
chondrial DNA to their offspring.44 Some commentators accordingly regard
MRT as involving a modification of the “human germline.”45
The United Kingdom became the first country to approve the technique
in 2016.46 The first known case of MRT, however, took place in Mexico.47
Dr. John Zhang, a New York doctor, assisted an American patient in using
MRT after the patient had already lost two children to early deaths from
DNA DISORDERS: AN ETHICAL REVIEW 27–28 (2012), https://nuffieldbioethics.
org/wp-content/uploads/2014/06/Novel_techniques_for_the_prevention_of_
mitochondrial_DNA_disorders_compressed.pdf.
41. See, e.g., PARLIAMENTARY OFFICE OF SCIENCE AND TECHNOLOGY, PREVENTING
MITOCHONDRIAL DISEASE, 2013, HOUSES OF PARLIAMENT 431, at 2 (UK) (pro-
viding an overview of mitochondrial disease and potential treatments as part of
the United Kingdom preparation to consider approving MRT).
42. Id.
43. Id.
44. See Mark S. Frankel & Brent T. Hagen, Germline Therapies, 11 NUFFIELD
COUNCIL ON BIOETHICS (May 2011), http://nuffieldbioethics.org/wp-content/
uploads/Germline_therapies_background_paper.pdf (observing that while boys
and girls can both develop mitochondrial diseases, only girls pass on mitochon-
drial DNA to their offspring).
45. Lewis, supra note 36, at 1249–50 (describing controversy but concluding that
the concept of a “human germline” has not been definitely defined and ques-
tioning whether it should include mutations causing birth defects); Frankel &
Hagen, supra note 44, at 1, 5–6 (observing that some, but not all, researchers
and clinicians restrict the definition of germline modification solely to the mod-
ification of nuclear DNA).
46. Michael Le Page, UK Becomes First Country to Give Go Ahead to Three-
Parent Babies, NEW SCIENTIST (Dec. 15, 2016), https://www.newscientist.com/
article/2116407-uk-becomes-first-country-to-give-go-ahead-to-three-parentba-
bies/ (“[The United Kingdom’s] Human Fertilisation and Embryo Authority
has given a cautious go-ahead to the use of mitochondrial replacement therapy
to prevent mitochondrial disorders, which can be fatal.”).
47. See Jessica Hamzelou, Exclusive: World’s First Baby Born with New “3 Par-
ent” Technique, NEW SCIENTIST (Sept. 27, 2016), https://www.newscientist.
com/article/2107219-exclusive-worlds-first-baby-born-with-new-3-parenttech-
nique/.
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mitochondrial disease and had miscarriages caused by the mutation.48 Initial
research had focused on the use of donor embryos,49 but the patient, who was
Muslim, preferred to use a donor egg. So, Dr. Zhang transferred nuclear
DNA from the intended parents to an unfertilized embryo, resulting in the
birth of a healthy child with mitochondrial DNA only from the donor.50
When Dr. Zhang took steps to form a company that offers the procedure, the
FDA threatened to take action against him if he did so.51 A subsequent child,
however, has been born using MRT in the Ukraine.52
A third example involves the use of egg specific stem cells to boost
fertility. While these techniques use the intended parents’ own cells, and thus
do not introduce donor DNA, they may alter the DNA that the resulting chil-
dren transmit to their offspring from that which would occur through in vivo
reproduction.53 These techniques involve the use of gamete specific stem
cells to create new eggs and sperm, or to boost the efficacy of existing ones.54
At one time, scientists believed that a woman had all the eggs she would
ever have inside her body at birth.55 In the last few years, however, research-
ers have discovered that women have egg specific stem cells in their ovaries,
which the researchers believe can be coaxed in to developing new, mature
48. Id.; see also Michelle Roberts, First ‘Three Person Baby’ Born Using New
Method, BBC NEWS (Sept. 27, 2016), http://www.bbc.com/news/health-
37485263.
49. For description of the differences, see Glenn Cohen, Circumvention Medical
Tourism and Cutting Edge Medicine: The Case of Mitochondrial Replacement
Therapy, 25 IND. J. GLOBAL LEGAL STUD. 439, 441 n.6 (2018).
50. Hamzelou, supra note 47.
51. See Ariana Eunjung Cha, FDA Cracks Down on Company Marketing ‘Three-
Parent’ Babies, WASH. POST (Aug. 8, 2017, 7:04 AM), https://www.washing
tonpost.com/news/to-your-health/wp/2017/08/07/fda-cracks-down-on-company
-marketing-three-parent-babies/?utm_term=.0562ad833f54.
52. See Akshat Rathi, The World’s Second Three-Parent Baby Has Been Con-
ceived Using a Controversial Technique, QUARTZ (Jan. 18, 2017), https://
qz.com/887916/the-worlds-second-three-parent-baby-has-been-conceived-us-
ing-a-controversial-pronuclear-transfer-ivftechnique (reporting that Ukrainian
doctors use the technique to assist a Ukrainian woman whose previous
pregnancies had failed to progress).
53. Zubin Master, Embryonic Stem-Cell Gametes: The New Frontier in Human
Reproduction, 21 HUM. REPROD. 857, 857 (2006).
54. Id.
55. See, e.g., Dori C. Woods et al., Oocyte Family Trees: Old Branches or New
Stems?, 8 PLOS GENETICS 1, 1 (2012), https://journals.plos.org/plosgenetics/
article?id=10.1371/journal.pgen.1002848 (considering whether women’s ova-
ries can produce new eggs in adulthood).
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eggs.56 A team including researchers from Israel and Cambridge University
has announced that they have been able to produce new eggs from the stem
cells in the lab.57 The French declared in 2015, that they had created new
sperm in the lab, using sperm specific stem cells in a similar fashion.58 These
developments are a potential game changer for ART because doctors could
then produce an unlimited number of new gametes for older patients or pa-
tients unable to reproduce because of the destruction of their existing sperm
and eggs.59 The ability to produce an unlimited gamete supply would also
make it easier to select for disease free embryos—or to select for embryos
with desired traits.60 Without further manipulation, however, this technology
would not be able to introduce new traits outside of those within the intended
parents’ existing genome.61
While these technologies are not yet ready for human use, a Boston
company, OvaScience, created a procedure called “AUGMENT.”62 This pro-
cedure was designed to extract a woman’s egg specific stem cells from her
ovaries, and inject them into her mature eggs with the hope of boosting the
woman’s ability to produce a successful pregnancy.63 OvaScience research-
56. Id.; see also HENRY T. GREELY, THE END OF SEX AND THE FUTURE OF HUMAN
REPRODUCTION 91–93 (2016) (describing the prospect of creating new gametes
from stem cells).
57. Eli Y. Adashi et al., Stem Cell-Derived Human Gametes: The Public Engage-
ment Imperative, 25 CELL PRESS REVS. 165, 165 (2019); David Shamah, Cell
Breakthrough a Step Toward Curing Infertility, TIMES OF ISR. (Dec. 24, 2014,
7:14 PM), https://www.timesofisrael.com/cell-breakthrough-may-let-post-
menopausal-women-give-birth/.
58. French Lab Claims Breakthrough with World’s First Lab Grown Sperm,
STRAITS TIMES (May 8, 2015, 10:02 PM), https://www.straitstimes.com/world/
europe/french-lab-claims-breakthrough-with-worlds-first-lab-grown-sperm.
59. See, e.g., Kelly Servick, These Lab-Grown Human Eggs Could Combat Infer-
tility—If They Prove Healthy, SCI. MAG. (Feb. 8, 2018, 7:01 PM), https://
www.sciencemag.org/news/2018/02/these-lab-grown-human-eggs-could-com
bat-infertility-if-they-prove-healthy.
60. Rob Stein, Scientists Create Immature Human Eggs From Stem Cells, NAT’L
PUB. RADIO (Sept. 20, 2018, 2:00 PM), https://www.npr.org/sections/health-
shots/2018/09/20/649552734/scientists-create-immature-human-eggs-from-
stem-cells.
61. See Inmaculada Moreno et al., Artificial Gametes from Stem Cells, 42 CLINICAL
& EXPERIMENTAL REPROD. MED. 33, 40 (2015); see Adam Watkins, First
Working Eggs Made From Stem Cells Points to Fertility Breakthrough, CON-
VERSATION (Oct. 17, 2016, 11:00 AM), http://theconversation.com/first-work
ing-eggs-made-from-stem-cells-points-to-fertility-breakthrough-67192.
62. Karen Weintraub, Rejuvenating the Chance of Motherhood?, MIT TECH. REV.
(Dec. 9, 2016), https://www.technologyreview.com/s/603065/rejuvenating-the-
chance-of-motherhood/.
63. Id.; Lewis, supra note 36, at 1280.
40 SMU Science and Technology Law Review [Vol. XXIII
ers theorized that some women, especially older women, have difficulty re-
producing because of the poor quality of their eggs.64 Adding stem cells
might then serve the same purpose as Saint Barnabas’s addition of donor
cytoplasm; it might improve the quality of the eggs’ mitochondria and over-
all health.65
Before OvaScience could try the technique, however, the FDA sent the
company a letter indicating the technique required preclearance review
before it could be used in the United States.66 OvaScience decided that it
could not raise the funding necessary to comply with the FDA requirements,
and instead introduced the technique abroad.67 It announced the birth of the
first baby born using the technique in Toronto in 2015, and after that at-
tempted to market AUGMENT internationally with some success.68 Over
time , however, doubts arose as to whether AUGMENT in fact enhanced the
likelihood of pregnancy,69 and OvaScience was hit with a securities suit that
ultimately caused the sale of the company.70 By then, however, a number of
babies had been born abroad through pregnancies produced with the use of
the technique.71 There is no analysis of what impact, if any, AUGMENT has
64. Leiser, supra note 40, at 418; Weintraub, supra note 62.
65. Leiser, supra note 40, at 420.
66. Lewis, supra note 36, at 1280. The letter stated that:
Our understanding is that your autologous mitochondrial transfer product,
AUGMENT, consists of cells isolated from a biopsy of ovarian tissue,
which are processed to extract mitochondria that are then introduced into
other reproductive tissues during the IVF process. The removal of mito-
chondria and introduction into other reproductive tissue appears to be
more than minimal manipulation. This is based on the limited information
available; please note that the addition of mitochondrial DNA to other
reproductive tissue may raise additional regulatory concerns.
67. Don Seiffert, OvaScience to Focus on Baby-Making Efforts Overseas, BOS.
BUS. J. (Jan. 15, 2014, 2:06 PM), https://www.bizjournals.com/boston/blog/bio
flash/2014/01/ovascience-to-focus-baby-making.html.
68. See Carbone & Madeira, supra note 36, at 97.
69. See Dahhan v. OvaScience, Inc., 321 F. Supp. 3d 247, 250 (D. Mass. 2018)
(asserting that the “real pregnancy success rate was approximately 27% of the
Canadian patients, and 23.5% for all 34 patients (including the non-Canadian
patients)” while “the success rate of IVF without AUGMENT for a similar
patient population is 33%.”).
70. See id. at 247 (rejecting OvaScience’s motion to dismiss); see Millendo Thera-
peutics Announces Successful Merger Completion with OvaScience, Inc., BIOS-
PACE.COM (Dec. 7, 2018), https://www.biospace.com/article/releases/millendo-
therapeutics-announces-successful-merger-completion/.
71. Dahhan, 321 F. Supp. 3d at 250–51 (discussing the number of patients).
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had on the resulting children.72 It is possible that the children have mitochon-
drial (or even nuclear) DNA from the stem cells that they will pass on to their
offspring.73 It is also quite possible that the introduction had no impact at all
on the resulting children.74 Yet, if AUGMENT had its intended effect of
boosting the efficacy of the intended mother’s mitochondria, it could well
alter the cell’s mitochondrial DNA in ways that would be passed to offspring
along the female line.75
These three developments—the introduction of donor cytoplasm, MRT,
and AUGMENT—all involve changes that could be transmitted to offspring,
thus altering the germline (as least of the mitochondrial DNA) in ways that
would not occur naturally.76 All three were done by fertility clinics who sim-
ply decided to try the techniques without human trials or advance regulatory
approval.77 None of the three involved public funding, and all were done with
the intention of using a technique that could be (or was) offered to paying
customers before any kind of testing indicating safety or efficacy was estab-
lished.78 There is no indication that use of the procedure caused harm to any
of the resulting children, though there is also no way at this point to know for
sure, and it is still too early to inquire about future generations.79 These cases,
however, provide a model for innovation in ART. In some of the cases,
72. See Andy Coghain, First Baby Born with IVF that Uses Stem Cells to Pep Up
Old Eggs, NEW SCIENTIST (May 8, 2015), https://www.newscientist.com/arti-
cle/dn27491-first-baby-born-with-ivf-that-uses-stem-cells-to-pep-up-old-eggs/
(stating that even though a baby was born after Augment treatments, it was
impossible to prove that the treatment was the reason for the success. Further-
more, “‘[t]here’s lack of evidence of efficacy, efficiency, and safety’ and ‘ma-
nipulation of the embryo at that very sensitive time could cause more problems
for the nuclear genome, which is why safety data is critical.’”).
73. Id. (discussing similar research that had been conducted in 2001, which re-
sulted in the babies carrying extra mitochondria from the donor cell).
74. Dahhan, 321 F. Supp. 3d at 250 (discussing data showing no increase in preg-
nancy rates).
75. The changes would not, however, introduce any genetic material from sources
other than the intended parents. See Lewis, supra note 36, at 1280 (describing
use of woman’s own mitochondria).
76. See PREVENTING MITOCHONDRIAL DISEASE, supra note 41 (stating that mtDNA
and nDNA found in an egg constitutes the germinline that the eventual off-
spring will carry and transmit to any of their future children. Therefore “any
changes made to DNA by using such treatments are essentially irreversible”).
77. See Daar, supra note 36 (observing that after the FDA said in 2001 that any
further use of cytoplasmic injection would require an Investigational New Drug
application, the practice ceased throughout the United States); see Lewis, supra
note 36, at 1280; see Cha, supra note 51.
78. See Daar, supra note 36; see Lewis, supra note 36, at 1280; see Cha, supra
note 51.
79. See Coghain, supra note 72.
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animal testing preceded the initial use, but the first human experimentation
occurred because fertility doctors simply decided, like Dr. He in China, to try
it on patients.80 In considering CRISPR, it is important to assess how likely
innovation in the use of new techniques is to occur in the future.
II. INNOVATION AND THE CHANGING ART LANDSCAPE
Innovation in ART has gone through a series of changes reflecting the
intersection of the regulatory landscape in the United States and the available
sources of ART funding. Development of CRISPR will take place in a very
different funding environment than Saint Barnabas’s experimentation with
cytoplasm transfer in the nineties.81 These changes will involve the growing
consolidation of fertility practices with increasing returns to scale, the use of
brokers and platforms to expand geographical research, the growing ability to
exploit international differences in price and regulation, the greater availabil-
ity of private funding from billionaire philanthropists and private equity in-
vestors, and finally what may be changing demand for ART from better
organized patient populations and older women seeking to extend their fertil-
ity.82 This section will examine that changing landscape before turning to
CRISPR itself.
A. Old Story: Complacent Cartels
At one time, federal funding constituted the major source of biomedical
funding, with a large part of that funding going to universities for basic re-
search.83 Much of the federal oversight of biomedical developments was tied
to the research funding.84 In addition, commercialization of the products of
that research tended to take place in one of two ways. Either the research
contributed to medical procedures, which typically depended on insurance
reimbursement to win acceptance.85 The insurance companies, in turn, in-
sisted on transparency and accountability in assessing the suitability of the
80. Greely, supra note 1, at 116.
81. See Carbone & Madeira, supra note 36, at 94 (describing St. Barnabas’s
procedures).
82. Id.
83. See Kenneth Sutherlin Dueker, Biobusiness on Campus: Commercialization of
University-Developed Biomedical Technologies, 52 FOOD & DRUG L.J. 453,
457 (1997).
84. See Note, Guiding Regulatory Reform in Reproduction and Genetics, 120
HARV. L. REV. 574, 579 (2006).
85. Robert J. Levine, Federal Funding and the Regulation of Embryonic Stem Cell
Research: The Pontius Pilate Maneuver, 9 YALE J. HEALTH POL’Y L. & ETH-
ICS 552, 561 (2009) (“Because insurance coverage for ART is quite limited,
reimbursement requirements fail to promote quality care.”).
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procedures.86 Alternatively, the research might contribute to drug develop-
ment, with drugs dependent on FDA preclearance to be sold in the American
market.87 For approval, the FDA requires compliance with research protocols
establishing safety and efficacy through closely monitored clinical trials.88
ARTs have largely developed outside of this process. The Dickey-
Wicker Amendment, which has been attached to every Department of Health
and Human Services appropriations bill since 1996, bans federal funding for
embryo research.89 At least initially, insurance coverage was limited.90 While
the drugs used in the ART require FDA approval, fertility techniques origi-
nally did not.91
As a result, fertility clinics sometimes seemed to be the “wild west” of
medicine.92 IVF clinics operated with private research funds and few external
forces existed to slow the work of the clinics.93 Further, once the clinics were
established, they enjoyed strong public support that limited legislative ability
to restrict their activities.94 Regulation of the industry has involved a tacit
compromise: “no laws are passed that even tangentially sanction embryo de-
struction and no laws are passed that intrude on the profitability of fertility
treatments.”95 That compromise serves the interests of both sides.96 Religious
groups like the Catholic Church, which opposes IVF altogether, consistently
86. Id.
87. See Dueker, supra note 83, at 455 (describing how the biggest business benefi-
ciary of university basic research was the pharmaceutical industry).
88. See Unapproved Drugs, FOOD & DRUG ADMIN., https://www.fda.gov/drugs/
enforcement-activities-fda/unapproved-drugs (last visited Mar. 8, 2020).
89. Philip J. Nickel, Ethical Issues in Human Embryonic Stem Cell Research, in
FUNDAMENTALS OF THE STEM CELL DEBATE: THE SCIENTIFIC, RELIGIOUS, ETH-
ICAL, AND POLITICAL ISSUES 62, 74 (Monroe et al. eds., 2008).
90. See June Carbone & Naomi Cahn, Embryo Fundamentalism, 18 WM. & MARY
BILL RTS. J. 1015, 1034 (2010) (noting that health insurance policies rarely
cover IVF).
91. See generally Lewis, supra note 36 (describing FDA assertion of jurisdiction).
92. See, e.g., Judith Daar, Federalizing Embryo Transfers: Taming the Wild West
of Reproductive Medicine?, 23 COLUM. J. GENDER & L. 257, 258 (2012).
93. Guiding Regulatory Reform in Reproduction and Genetics, supra note 84, at
587.
94. Id. at 584 (observing that the “strong public acceptance of IVF that ensued,
coupled with an entrenched economic force in the form of a private fertility
industry, may have then solidified the early deadlock into a long-term deregu-
latory norm that has persisted to this day.”).
95. Carbone & Cahn, supra note 90, at 1015.
96. See id. at 1032 (“Legislative and regulatory oversight of assisted reproduction
has been characterized by moral posturing and regulatory gridlock.”).
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object to laws that implicitly or explicitly authorize ART.97 As a result, the
ability to get laws passed addressing ART practices, like surrogacy, has his-
torically required restrictions on their applicability to same-sex couples—
restrictions vigorously opposed by many of the laws’ proponents.98 The ma-
jor regulation Congress has been able to get through for IVF itself involves
reporting requirements—the clinics must report their success rates.99
The wild west moniker, however, which reflects the lack of more direct
regulation and is descriptive of early clinics is in many ways misleading.100
Establishing the initial fertility clinics in the United States did require an
entrepreneurial spirit, and with the creation of a new line of medical prac-
tices, ethical abuses occurred, notably the use of donor sperm from the fertil-
ity doctors performing the procedures.101 Further, once the industry was
established, it involved a cartel-like structure more like cosmetic surgery than
97. See, e.g., Joseph Card. Ratzinger, Instruction on Respect for Human Life in Its
Origin and on the Dignity of Procreation Replies to Certain Questions of the
Day, CONGREGATION FOR THE DOCTRINE OF THE FAITH (Feb. 22, 1987), http://
www.vatican.va/roman_curia/congregations/cfaith/documents/rc_con_cfaith_
doc_19870222_respect-for-human-life_en.html (determining that both heterol-
ogous and homologous artificial fertilization are unacceptable); John M. Haas,
Begotten Not Made: A Catholic View of Reproductive Technology, U.S. CONF.
CATH. BISHOPS, http://www.usccb.org/issues-and-action/human-life-and-dig-
nity/reproductive-technology/begotten-not-made-a-catholic-view-of-reproduc-
tive-technology.cfm (“One reproductive technology which the Church has
clearly and unequivocally judged to be immoral is in vitro fertilization or
IVF.”) (last visited Feb. 29, 2020).
98. Carbone & Cahn, supra note 90, at 1045 (describing surrogacy provisions lim-
iting applicability to different sex couples).
99. The United States Fertility Clinic Success Rate and Certification Act of 1992,
42 U.S.C. §§ 263a-1–263a-7 (1994). Congress does find it easier to restrict
technologies that have not yet shown promise. See Russell A. Spivak et al.,
Germ-Line Gene Editing and Congressional Reaction in Context: Learning
from Almost 50 Years of Congressional Reactions to Biomedical Break-
throughs, 30 J.L. & HEALTH 20, 30 (2017) (detailing existing legislation on
genetic alterations); Paul Enriquez, Editing Humanity: On the Precise Manipu-
lation of DNA in Human Embryos, 97 N.C. L. REV. 1147, 1240 (2019) (sum-
marizing legal regulation of genetic alterations in embryos).
100. See, e.g., Daar, supra note 92 (calling it an “urban myth”). She emphasizes
instead that American reproductive practice, like all others areas of medicine,
“is subject to quality control through a variety of mechanisms, most notably
licensure of physicians by state-based medical boards, application of practice
standards established by professional societies, and private tort litigation.” Id.
at 262.
101. See, e.g., Jody Lynee Madeira, Uncommon Misconceptions: Holding Physi-
cians Accountable for Insemination Fraud, 37 L. & INEQ. 45, 45 (2019)
(describing doctors using their own sperm without informing patients).
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cancer treatment.102 However, a critical barrier to entry into the fertility busi-
ness is the need to recruit trained medical professionals, including reproduc-
tive endocrinologists who require twelve years of secondary education to be
properly certified.103 Fertility practices are then “subject to quality control
through a variety of mechanisms, most notably licensure of physicians by
state-based medical boards, application of practice standards established by
professional societies, and private tort litigation.”104 Without widespread in-
surance coverage or other third party subsidies, these practices catered to
high end patients able to pay out-of-pocket for high end procedures.105 De-
bora Spar describes the clinics as competing to serve wealthy clients, with
relatively high value, high profit services, rather than competing on price or
seeking to expand volume.106
Within these decentralized clinics,107 doctors might try new techniques,
such as Saint Barnabas’s use of cytoplasm transfer. Maureen Ott, one of the
women who gave birth using cytoplasm transfer, commented, “‘[w]e wanted
a baby so badly that we felt it was important to pursue every option availa-
ble.’”108 Clinic patients supported (and presumably paid for) experimentation
102. See Carbone & Madeira, supra note 36, at 77 (noting the decentralized, small
practice nature of most IVF centers).
103. How to Become a Fertility Specialist, DOCTORLY.ORG, http://doctorly.org/how-
to-become-a-fertility-specialist/ (last visited Feb. 25, 2020); See DEBORA SPAR,
A BABY BUSINESS: HOW MONEY, SCIENCE, AND POLITICS DRIVE THE COM-
MERCE OF CONCEPTION 33 (2006) (observing that the lengthy training necessary
to be able to do IVF creates barriers to entry); David Sable, How Entrepreneurs
Will Move IVF into the Future, FORBES (Feb. 3, 2018), https://www.forbes.com
/sites/davidsable/2018/02/03/how-entrepreneurs-will-move-ivf-into-the-future/
#41ae87a6554a (describing how fertility clinics focus on providing higher
quality care rather than expanded access).
104. Daar, supra note 92, at 262.
105. See Judith F. Daar, Accessing Reproductive Technologies: Invisible Barriers,
Indelible Harms, 23 BERKELEY J. GENDER L. & JUST. 18, 37 (2008) (observing
that insurance mandates have relatively little effect on fertility treatment usage
because those with insurance coverage are the patients most likely to be able to
afford fertility treatments on their own).
106. SPAR, supra note 103, at 34 (describing trade-offs in business models between
high volume, lower priced, routine services versus high-end, high profit, lower
volume customized services).
107. Fertility Clinics, CAPSTONE PARTNERS, http://capstoneheadwaters.com/sites/de
fault/files/Capstone%20Fertility%20Clinics%20Report%20Q1%202017.pdf#
page=4 (last visited Mar. 8, 2020) (observing that the U.S. Fertility Clinic in-
dustry is highly fragmented and is comprised mainly of small regional clinics).
108. June Carbone, Toward A More Communitarian Future? Fukuyama As the Fun-
damentalist Secular Humanist, 101 MICH. L. REV. 1906, 1920 (2003) (quoting
Healthy Baby Born After World’s First Successful Cytoplasmic Transfer, BUS.
WIRE (July 18, 1997), WL, Business Wire Plus Database).
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with an untested technique.109 Yet, such clinics do not have the resources for
large scale or carefully controlled studies establishing the safety and efficacy
of these procedures.110 Dr. Jamie Grifo, who participated in the Saint Barna-
bas procedures, explained, in response to a question as to why the clinic did
not do animal testing, “[a]nimal colonies cost a fortune to maintain,” he said
and “we have no research dollars.”111
Nonetheless, the clinics are sensitive to negative publicity. Just as they
did not have the funds for animal testing or large scale human trials, neither
did they have the funds to challenge the FDA’s assertion of jurisdiction, even
though the legal basis for jurisdiction is questionable.112 Once the FDA re-
quired preclearance for the use of such techniques, they stopped being done
in the United States.113 Over the next two decades, however, the environment
for fertility research changed dramatically.
B. New Story: Privatization and Globalization
Over the last twenty years, the environment for ART innovation has
changed substantially. Many of the changes involve the changing health care
landscape and the increasing role of private funding across the board. Some
of the changes, however, have affected ARTs with particular force. These
changes have produced increasing returns to scale, encouraged the consolida-
tion of fertility and other medical services, and increased the geographic
reach of fertility services.114 Other changes have seen an increase in the role
and availability of private funding, including both philanthropic efforts and
private equity funding encouraging commercialization of techniques.115
Taken together, they provide a more promising landscape for future genetic
109. Id.
110. Id. at 1921.
111. Nigel Hawkes, Baby Race That May Be Too Fast for Safety, TIMES, Oct. 10,
1998, at 4.
112. See, e.g., Lewis, supra note 36, at 1257; Richard A. Merrill & Bryan J. Rose,
FDA Regulation of Human Cloning: Usurpation or Statemanship?, 15 HARV.
J.L. & TECH. 85, 102 (2001); Enriquez, supra note 99, at 1147, 1148 (question-
ing the constitutionality of the FDA restrictions).
113. Indeed, for a time, Dr. Grifo moved his research to China. See Antonio
Regalado & Karby Leggett, Fertility Breakthrough Raises Questions About
Link to Cloning, WALL ST. J., Oct. 13, 2003, at 1A (reporting that a team of
Chinese and American doctors were expected to announce that they had cre-
ated the first human pregnancy using a DNA-swapping technology that would
prefigure the later use of MRT).
114. Hamid Yunis & Bella North, Spotlight on Private Equity in the Fertility Sector,
NAT’L L. REV. (May 23, 2019), https://www.natlawreview.com/article/spot-
light-private-equity-fertility-sector.
115. Id.
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modification technologies—if they prove effective in solving the reproduc-
tive issues that arise from genetically transmitted diseases.
1. Private Funding
While federal funds once supplied the vast bulk of research funding, this
is no longer true. By the nineties, private funding began to eclipse federal
dollars in biomedical research generally.116 More recently, private equity and
venture capital investors have begun to pay greater attention to the fertility
industry.117 This private funding takes two principal forms.
The first is called “billionaire philanthropy.”118 With growing income
inequality, concentrated charitable contributions can have more clout, partic-
ularly in controversial areas of research.119 For example, philanthropist Kath-
arine McCormack funded development of the birth control pill, the Susan
Thompson Buffett Foundation contributed to the development of safer IUDs,
and the Bill and Melinda Gates Foundation has funded international contra-
ceptive efforts.120 They have done so, in part, because of the inconsistent
political will to fund such efforts, given religious opposition and cultural di-
vision.121 In addition, private philanthropists and patient groups have at-
tempted to jumpstart funding in neglected areas, often ones that affect their
families.122 Research in Parkinson’s disease, autism, asthma, prostate cancer
and other common diseases received boosts in funding when private donors
decided to concentrate efforts in those areas.123 Private donors also seek to
support research that is “too obscure, too experimental, or too uncertain” to
116. Guiding Regulatory Reform in Reproduction and Genetics, supra note 84, at
579.
117. Yunis & North, supra note 114.
118. Kelsey Piper, How Billionaire Philanthropy Provides Reproductive Healthcare
When Politicians Won’t, VOX (Sept. 17, 2019, 8:10 AM), https://www.vox.
com/future-perfect/2019/9/17/20754970/billionaire-philanthropy-reproductive-
health-care-politics.
119. See id.
120. Id.
121. Id.
122. See Alice Dickow, Does Anyone Care? A Case Study of Funding Research on
Rare Diseases, INSIDE PHILANTHROPY (Oct. 18, 2018), https://www.insidephi
lanthropy.com/home/2018/10/18/does-anyone-care-a-case-study-of-funding-re-
search-on-a-rare-diseases.
123. How Four Philanthropists Are Innovating Medical Research, BRIDGESPAN
GRP. (Sept. 26, 2013), https://www.bridgespan.org/insights/blog/give-smart/
how-philanthropists-innovate-medical-research.
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attract other funding.124 With rare diseases, family and friend fundraising ef-
forts often make more of a difference than other sources.125 These private
funding sources, while small in comparison with industry-based or public
funds, typically come with fewer strings attached.126
The second source of private funding comes from venture capital and
private equity firms.127 Venture capital firms typically invest in start-ups,
helping to get such companies off the ground.128 Venture capital investors
acquire an equity interest in the company, hoping to benefit from their invest-
ment when the company takes off, is sold, or goes public.129 By contrast,
private equity firms pool money from multiple investors and acquire shares
in private companies (or in public companies that they hope to take pri-
vate).130 Large institutional investors are more common in the private equity
world, and they often plan to hold the shares they acquire for relatively short
periods.131 Both venture capital and private equity firms seek to profit from
their investments, and often pressure the companies in which they invest to
grow quickly and/or rapidly increase their profitability.132
In the past, outside investment of this type has not played an important
role in the development of fertility treatments, but venture capital and private
equity firms increasingly see the fertility industry as a new opportunity.133
Industry analysts emphasize the opportunity for consolidation as the industry
experiences increasing returns to scale.134 They emphasize women’s later age
of childbearing and increasing demand for such services.135 Analysts also
124. Michael Anft, When Scientific Research Can’t Get Federal Funds, Private
Money Steps In, CHRON. PHILANTHROPY (Feb. 8, 2015), https://www.philan-
thropy.com/article/When-Scientific-Research/151777#.
125. Dickow, supra note 122.
126. See How Four Philanthropists Are Innovating Medical Research, supra note
123.
127. Rebecca Robbins, Investors See Big Money in Infertility. And They’re Trans-
forming the Industry, STAT (Dec. 4, 2017), https://www.statnews.com/2017/12/
04/infertility-industry-investment/.
128. Id.
129. Private Equity vs. Venture Capital: What’s the Difference?, INVESTOPEDIA
https://www.investopedia.com/ask/answers/020415/what-difference-between-
private-equity-and-venture-capital.asp#targetText=private%20equity%20is%20
investment%20capital,potential%20for%20long%2Dterm%20growth. (last up-
dated Mar. 19, 2020).
130. Id.
131. Id.
132. See id.
133. See Yunis & North, supra note 114.
134. Fertility Clinics, supra note 107.
135. Id.
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note the improving success rates of existing fertility treatments and the pos-
sibilities for technological innovation.136 In addition, investors see potential
gains from increased collaboration, better advertising, international opportu-
nities, and more sophisticated development strategies.137
Ultimately, increased private funding, both philanthropic and invest-
ment driven, may involve less direct oversight than government funding. But
particularly when the funding comes from commercial investors, it may in-
clude pressure to quickly ramp up new products or unneeded or untested
procedures.138
2. Pressures for Consolidation
Driving some of the investment opportunities is the growing consolida-
tion in the fertility industry. The pressure to consolidate comes in large part
from increasing returns to scale.139 Consolidation is occurring across the
health care industry, and some of these trends affect fertility clinics as
well.140 Chief among these forces are the Electronic Records Act and accom-
panying privacy regulations, which involve not only transition costs, but also
continuing compliance monitoring of the privacy requirements.141 In addi-
tion, innovation itself may increase consolidation to the extent it requires
investment in new and more expensive machinery, more varied treatments,
or inclusion of larger groups of specialists in providing care.142
Changing insurance requirements also affect the returns to scale.143 Fif-
teen states mandate at least some coverage of IVF, though they do not neces-
136. Id.
137. See Yunis & North, supra note 114.
138. Aaron Harris, Why VCs Sometimes Push Companies to Burn Too Fast, YCOM-
BINATOR (Nov. 21, 2016), https://blog.ycombinator.com/why-vcs-sometimes-
push-companies-to-burn-too-fast/ (describing short-term time frames for ven-
ture capital investors); Robbins, supra note 127 (observing that some clinics
have resisted private equity investors because of the fear that these investors
emphasize increased volume to the detriment of patient care).
139. Carbone & Madeira, supra note 36, at 81.
140. See id. at 80 (observing that doctors have been selling private practices to
larger hospital associations with increasing concentration since the nineties).
141. Paul R. Brezina et al., How Obamacare Will Impact Reproductive Health, 31
SEMINARS REPROD. MED. 189, 194 (2013) (discussing the high cost of the tran-
sition to electronic records and the need for continuing record maintenance and
compliance monitoring).
142. Carbone & Madeira, supra note 36, at 81–83 (observing that larger groups
enjoy greater discounts in acquiring new equipment).
143. See id. at 92–93.
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sarily contain the full range of fertility treatments.144 Market pressures,
however, have been gradually increasing insurance coverage, particularly for
the high-end employees most likely to delay childbearing.145 In 2013, sixty-
five percent of businesses with over 500 employees covered an initial evalua-
tion by a fertility specialist, with twenty-seven percent paying for IVF and
forty-one percent paying for IVF related drugs.146
Greater insurance coverage, in turn, changes the dynamics of fertility
practices.147 The most direct impact is the increased demand for services.148
Insurance companies also limit the services they will reimburse and the
prices that they will pay for these services.149 Debora Spar explains that
greater insurance coverage—or even the threat of insurance—shifts fertility
business models toward an emphasis on attracting a larger volume of patients
who want more routine (and lower priced) services that insurers will
reimburse.150
An additional factor that may influence the future development of the
industry is increased integration of fertility services with genomic informa-
tion.151 In an era of personalized medicine, doctors have become increasingly
aware of genetic factors that may increase the risk of infertility or of the
transmission of genetic traits that increase the risk of disease in offspring.152
For patients with diagnosed disorders, insurance companies may cover a
larger part of the cost of the testing and treatments associated with reproduc-
tion.153 At least one industry analyst has suggested the development of spe-
cialized fertility centers designed specifically to integrate patient care with
reproductive services.154
144. Tara Siegel Bernard, Insurance Coverage for Fertility Treatments Varies
Widely, N.Y. TIMES (July 25, 2014), http://www.nytimes.com/2014/07/26/
your-money/health-insurance/insurance-coverage-for-fertility-treatments-varies
-widely.html (noting that “[o]f the states that mandate coverage, only eight—
Arkansas, Connecticut, Hawaii, Illinois, Maryland, Massachusetts, New Jersey
and Rhode Island—require some level of coverage for in vitro fertilization”).
145. See Carbone & Madeira, supra note 36, at 90.
146. Bernard, supra note 144.
147. See Carbone & Madeira, supra note 36, at 87.
148. SPAR, supra note 103, at 34.
149. Id.
150. Id.
151. See David Sable, The Seven Trends that Define the Future of IVF, FORBES
(Feb. 28, 2015, 4:53 PM), http://www.forbes.com/sites/davidsable/2015/02/28/
the-seven-trends-that-define-the-future-of-ivf/.
152. See Carbone & Madeira, supra note 36, at 89–90.
153. Id.
154. David Sable, Embryologist-Owned IVF Labs and Other Keys to the Future of
Preventive Medicine, FORBES (July 18, 2019, 11:11 AM), https://www.forbes.
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These changes in fertility markets may simultaneously increase the size
of existing clinics and contribute to greater segmentation of the markets.
Larger clinics already serve more populous states with greater insurance cov-
erage, while most clinics remain relatively small and focused on custom ser-
vices for patients who pay out of pocket.155 This segmentation may continue
to increase further in the future.156
3. Patient Recruitment and Globalization
The pressure to increase volume has increased the need to advertise fer-
tility services and the desire to increase clinics’ geographic reach.157 Industry
changes include both efforts to increase access and demand, and the creation
of platforms that match patients and services.158 These platforms contribute
to greater market segmentation.159 Some platforms, for example, seek to re-
cruit wealthy patients to the United States for services, while sending poorer
Americans to less expensive clinics abroad.160 They may also exploit juris-
dictional differences in regulation.161 For example, advertising the ability to
engage in embryo sex selection is a practice banned in many countries.162
Some industry analysts have invested in efforts to market “one-stop-
shop fertility care, starting long before a woman is ready to conceive.”163 The
idea is to recruit younger patients, persuade them to monitor their fertility
com/sites/davidsable/2019/07/18/embryologist-owned-ivf-labs-and-other-keys-
to-the-future-of-preventive-medicine/#6b05589c5c21.
155. SPAR, supra note 103, at 58 (observing that most clinics “are either very high
volume or very high tech”).
156. See id. at 58–60.
157. See Fertility Market Overview, HARRIS WILLIAMS & CO. (May 2015), http://
www.harriswilliams.com/sites/default/files/content/fertil-
ity_industry_overview_-_2015.05.19_v10.pdf (commenting on the highly frag-
mented nature of the U.S. market and efforts to increase consolidation and
geographic reach).
158. See Carbone & Madeira, supra note 36, at 106; see Sable, supra note 151.
159. See Carbone & Madeira, supra note 36, at 106.
160. See id.; see Our Centers and Staff, FERTILITY INSTS., http://www.fertility-
docs.com/about-us/clinics-and-staff.php (last visited Apr. 1, 2020); see Interna-
tional Programs, FERTILITY INSTS., http://www.fertility-docs.com/programs-
and-services/international-programs.php (last visited Apr. 1, 2020).
161. Carbone & Madeira, supra note 36, at 100.
162. Meredith Leigh Birdsall, An Exploration of “The ‘Wild West’ of Reproductive
Technology”: Ethical and Feminist Perspectives on Sex-Selection Practices in
the United States, 17 WM. & MARY J. WOMEN & L. 223, 226 (2010) (describ-
ing that “more and more couples from other countries are coming to the United
States for sex-selection procedures to which they are denied at home”).
163. Robbins, supra note 127.
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through new apps and other devices, encourage them to consider freezing or
donating their eggs, and proactively identify potential barriers to reproduc-
tion.164 A private equity firm in New York has created a national network of
fertility clinics and frozen egg banks, called “Prelude Fertility.”165 It plans to
use social media to encourage younger patients to become more aware of
fertility issues and to begin to plan for them years in advance.166
In the meantime, existing agencies act as matchmakers between fertility
service patients and providers.167 Clinics that recruit gamete donors and pro-
vide surrogacy services already operate on a national and international ba-
sis.168 Some countries ban surrogacy while others offer the services at lower
prices.169 Even within the United States, the fifty states vary widely in the
regulation of surrogacy.170 Agencies exist that recruit broadly, matching pa-
tients and providers.171 These agencies contribute to the increasing volume of
fertility patients; they also make it easier to evade regulatory restrictions.172
Taken together, these efforts reflect a growing demand for fertility ser-
vices, with some designed to increase the demand even more. As that occurs,
new platforms have arisen that consolidate fertility services within a frame-
work that seeks to meet customer needs—at least for patients able to pay.
This new world of globalized, privatized reproductive medicine provides the
framework for considering the future of genetic alteration.
164. Id.
165. Amanda Cantrell, This Venture Capital Fund Wants to Get You Pregnant, IN-
STITUTIONAL INV. (May 15, 2019) https://www.institutionalinvestor.com/article
/b1ff3x6hcl5wbb/This-Venture-Capital-Fund-Wants-to-Get-You-Pregnant.
166. Robbins, supra note 127.
167. Tamar Lewin, Coming to U.S. for Baby, and Womb to Carry It, N.Y. TIMES
(July 5, 2014), http://www.nytimes.com/2014/07/06/us/foreign-couples-head-
ing-to-america-for-surrogate-pregnancies.html.
168. See, e.g., id. (describing increase in international visitors coming to the United
States for surrogacy treatments).
169. See, e.g., Lisa C. Ikemoto, Reproductive Tourism: Equality Concerns in the
Global Market for Fertility Services, 27 L. & INEQ. 277, 282 (2009) (“The
most troubling aspects of reproductive tourism arise from the use of third par-
ties who furnish gametes and from surrogates who gestate babies for others. In
fact, the strongest critics of these practices use the term ‘trafficking’ rather than
‘tourism.”‘).
170. See June Carbone & Jody Lyneé Madeira, The Role of Agency: Compensated
Surrogacy and the Institutionalization of Assisted Reproduction Practices, 90
WASH. L. REV. ONLINE 7, 14 (2015).
171. Id. at 25.
172. I. Glenn Cohen, Circumvention Tourism, 97 CORNELL L. REV. 1309, 1311
(2012) (describing rise of medical tourism designed to circumvent regulatory
obstacles).
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III. CRISPR AND THE FUTURE OF GENETIC MODIFICATION
In thinking about CRISPR’s potential to usher in germline genetic mod-
ifications, it is important to think about why a patient would want access to
the technology, and the circumstances in which doctors and scientists would
be tempted to make it available. In short, just like the development of surro-
gacy and gamete donation, the development of CRISPR technology is likely
to reflect underlying supply and demand motivations.
Approaching CRISPR this way sets up three questions. First, why
would Dr. He ever choose the patients he did for the first use of CRISPR to
edit a child’s genome?173 Second, what is the prospect for using CRISPR to
enhance the reproductive efforts of patients who would otherwise be infer-
tile? Third, is CRISPR a likely option for patients who could not otherwise
produce genetically related offspring without the risk of transmitting a dis-
ease? These three uses (and potential uses) of CRISPR may develop in dif-
ferent environments, with different implications for CRISPR’s impact on the
future of genomic germline modification.
A. What was Dr. He Thinking?
Dr. He’s choice of patients for the first experimentation with CRISPR in
the reproductive context is curious—and unjustifiable. As Hank Greely has
observed, the problems with the experiment are not just about germline edit-
ing.174 Greely concluded that even if the experiment had involved only so-
matic cells, with no germline alterations, it would have been “‘criminally
reckless’ as well as ‘grossly premature, and deeply unethical.’”175 The rea-
sons go to the basic protocols underlying scientific research.176
The first involves balancing the costs and benefits to the research sub-
jects. The first use of a new technique in a human is always inherently dan-
gerous because the consequences may not be knowable in advance.177 These
risks are magnified in embryos where the impact can affect the child’s devel-
opment over the course of a lifetime, and the genetic modifications can be
passed, perhaps in unpredictable ways, to offspring.178 As of yet, CRISPR
use has not been determined to be safe and effective in somatic cells—the
173. Greely uses the term “genome” to refer to changes in multiple genes. In addi-
tion, he prefers the term “edit” to “change” to distinguish intentional alterations
from naturally occurring ones. Greely, supra note 1, at 165.
174. Id. at 151.
175. Id.
176. Id. at 153.
177. Id.
178. Id.
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logical initial step in human use.179 Further, researchers are concerned about
identifiable risks associated with CRISPR use in embryos including the pos-
sibility that the CRISPR tool could unintentionally make changes in the
wrong places, producing potentially dangerous “‘off target’ effects.”180 The
desired edits could also have unpredictable effects, altering human function
in undesirable ways.181 CRISPR could succeed in altering some, but not all,
of the child’s target cells, which might undermine the intended benefit.182
Finally, CRISPR could “cause large deletions or duplications in DNA, with
unpredictable (but almost certainly not good) effects.”183
Weighed against these considerable risks are the limited potential bene-
fits from Dr. He’s procedure. The twins’ father was HIV positive carrying
the risk of HIV infection.184 Nonetheless, there are established ways of limit-
ing the risk of HIV infection or treating it after birth.185 Moreover, even if the
genetic alteration worked exactly as it was intended, there can be no certainty
that it would confer HIV immunity.186 The potential risks, therefore, almost
certainly outweighed the potential benefits for the resulting children—and
violated appropriate research protocols.187
Dr. He’s use of CRISPR therefore hardly provides a model for future
use. But it is worth considering what may have motivated the parents’ partic-
ipation. While sperm washing (that is, separation of the sperm from semen)
virtually eliminates the risk of infection, these services are not necessarily
available for HIV positive prospective parents in China.188 The investigation
into Dr. He’s activities indicated that “HIV carriers are not allowed to have
assisted reproduction.”189 The Chinese couples involved in the experiment
could thus have viewed participation as their only way to gain access to IVF
and possibly, therefore, their only way to have children at all or children
179. See Diane Nicol et al., Key Challenges in Bringing CRISPR-Mediated Somatic
Cell Therapy into the Clinic, 9 GENOME MED. 85 (2017) (describing safety
issues associated with CRISPR).
180. Greely, supra note 1, at 153.
181. Id. at 153–54.
182. Id. at 153. This appears to have happened in the case of the Chinese twins, with
uncertain results.
183. Id. at 153–54.
184. Id. at 116.
185. Id. at 155–56 (maintaining that with use of the proper techniques, the risk of
infection at conception “disappears entirely”).
186. Greely, supra note 1, at 156.
187. Id. at 163, 168. These protocols include not only the balancing of risks and
benefits, but provisions for appropriate follow-up care, informed consent, ad-
vance authorization and other provisions.
188. Id. at 165.
189. Id.
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without a risk of HIV transmission. While this raises additional ethical con-
cerns, principally about Dr. He’s potential conflicts of interest,190 it also
raises a different way to think about the potential future use of CRISPR.
What if, instead of thinking of CRISPR principally as a way to prevent dis-
ease transmission, it also became a way to facilitate fertility treatments? And
how would patients and medical professionals react if they saw CRISPR as
the last chance for a couple to have genetically related children? Dr. He’s
patients may well have been motivatd by such considerations, which reflect
legal regulation in China as much if not more than the medical advances
offered by the CRISPR technique.
B. CRISPR and the Fertility Industry
Imagine the following scenario: A woman in her twenties receives a
devastating cancer diagnosis. The doctors advise her that the cancer treat-
ments are likely to damage or destroy her eggs, making it unlikely that she
will be able to bear children in the future. She decides to retrieve and freeze
as many eggs as she can before the cancer treatments. Ten years later, she is
cancer free and ready to start a family. She thaws some of the eggs, fertilizes
them with her husband’s sperm, and tries to become pregnant. With the first
attempts, she does not become pregnant. Then, she succeeds in becoming
pregnant, but miscarries. She now has only one batch of eggs left. Five sur-
vive the thawing. By the time she is ready for the insemination, only three
are still viable. PGD indicate that all three of the remaining embryos have
serious genetic issues, with two embryos having two copies of the gene for
sickle cell anemia and therefore a high likelihood of producing the disorder.
By the time this occurs, CRISPR has been successfully used to edit the so-
matic cells associated with sickle cell, and embryo trials have been success-
ful in editing and removing the sickle cell genes from embryos. Should
CRISPR be used to edit the sickle genes to eliminate the possibility that the
embryos will develop into children with the disease?
Currently, doctors are unable to use CRISPR without running afoul of
the FDA’s requirement that fertility clinics receive FDA approval before do-
ing so.191 Researchers who want to apply for such approval will generally not
receive approval within time to benefit the patients, particularly if the re-
searchers waited until after the eggs were thawed and fertilized to request
approval.192 At least at present, there are not enough patients in the position
190. Id. (observing that this would have meant that Dr. He approached vulnerable
patients to propose an experiment from which he expected to benefit). On the
other hand, it might also mean that the twins would not have existed but for the
experiment, suggesting greater benefits than if the parents could easily access
sperm washing technology.
191. See supra text accompanying note 36.
192. Caroline Praderio, There’s a Dark Side to Egg Freezing That No One is Talk-
ing About, INSIDER (Mar. 22, 2017, 3:49 PM), https://www.insider.com/egg-
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of the cancer survivor to justify the costs ordinarily associated with the type
of clinical trials necessary to secure FDA approval.193
Therefore, when faced with the immediate needs of a patient, a fertility
clinic might decide to perform the procedure abroad.194 Then, assuming that
the procedure is proved safe and effective, the clinic might want to continue
to offer the option to other patients. The easiest way to do so would be to set
up a clinic that routinely offered the procedure in another country with little
regulation.195 When PGD was first offered, select clinics, in the United States
and abroad, often advertised their willingness to use the technique as a way
of increasing success rates for high risk patients.196 Today, clinics also adver-
tise their willingness to use the technique as a means of sex selection, another
controversial practice banned in many jurisdictions.197 It is thus easy to imag-
ine clinics offering the following packages of services:
(1) An increasing number of clinics today offer egg freezing services.198
The average woman who freezes her eggs does so around the age of
37, an age when women’s fertility is already beginning to wane.199
Industry critics worry that women who rely on frozen eggs may find
themselves with too few viable ones to achieve a pregnancy.200
freezing-failure-risks-2017-3.; See supra text accompanying note 36. The rider
would prevent FDA funding, which would affect approval for this process.
193. See, e.g., Carbone & Madeira, supra note 36, at 95, 97 (describing how OvaS-
cience developed its fertility procedures abroad because of a lack of funding to
conduct the trial necessary to win FDA approval).
194. For a description of how that was done with the first MRT procedure, see
Cohen, supra note 49.
195. Michelle J. Bayefsky, Comparative Preimplantation Genetic Diagnosis Policy
in Europe and the USA and its Implications for Reproductive Tourism, 3
REPROD. BIOMEDICINE & SOC’Y ONLINE 41, 42, 45 (2016).
196. Birdsall, supra note 162, at 228.
197. Id. (describing that more and more couples from other countries are coming to
the United States for sex-selection procedures that they are denied at home).
198. Praderio, supra note 192 (“The number of women who froze their eggs at US
fertility clinics grew by more than 700% between 2009 and 2013.”).
199. Kylie Baldwin, Six Things You Should Know If You Are Considering Freezing
Your Eggs, CONVERSATION (Apr. 3, 2018, 8:37 AM), https://theconversa-
tion.com/six-things-you-should-know-if-you-are-considering-freezing-your-
eggs-94039#targetText=however%2C%20the%20average%20age%20at,eggs
%20before%20you%20are%2036.
200. Praderio, supra note 192.
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(2) PGD can increase IVF success by allowing doctors to select health-
ier embryos for implantation. Reliance on PGD means that the abil-
ity to identify genetic defects is likely to increase in importance.201
(3) The delay in starting families, with or without egg freezing,202 may
increase the number of patients who lack healthy gametes.203 They
may wish to use PGD to screen the resulting embryos, and to use
CRISPR to edit the genomes of their limited supply of embryos (or
of the supply of gametes beforehand) to increase the likelihood of
producing a healthy infant.
(4) If doctors are engaged in genetic manipulation anyway, in order to
increase reproductive success, they may consider additional altera-
tions. For example, suppose that one of the cancer patient’s eggs has
a gene associated with premature aging, limiting the child’s poten-
tial lifespan.204 If the doctors are planning to edit that gene to pre-
vent premature aging anyway, they might also add a gene associated
with longer lifespan.205 With greater genomic knowledge and expe-
rience, fertility doctors could easily develop a menu of options for
genetic modification.206
While the number of women in the position to use such techniques to-
day is small, that could increase in the future.207 If the combination of better
screening and human genome editing were available, it might persuade even
more women to freeze eggs at younger ages. In addition, given the expense
of IVF, if it became relatively safe and inexpensive to use CRISPR, patients
201. In addition, in some cases, it might make sense to screen the gametes before
fertilization. See MACINTOSH, supra note 27, at 13–14 (discussing advantages
of editing gametes rather than embryos).
202. Quoctrung Bui & Claire Cain Miller, The Age That Women Have Babies: How
a Gap Divides America, N.Y. TIMES (Aug. 4, 2018), https://www.nytimes.com/
interactive/2018/08/04/upshot/up-birth-age-gap.html.
203. Over time, however, scientists expect to be able to create an unlimited supply
of new gametes from stem cells. See Greely, supra note 22, at 259 (estimating
that the ability to create an unlimited supply of new gametes may occur at
about the same time as CRISPR technology becomes more reliable).
204. See Sandra Rodrı́guez-Rodero et al., Aging Genetics and Aging, 2(3) AGING &
DIS. 186 (Apr. 28, 2011), https://www.ncbi.nlm.nih.gov/pmc/articles/PMC
3295054/ (observing that alteration in a single gene produces a remarkable dif-
ference in lifespans).
205. See MACINTOSH, supra note 27, at 19–20 (discussing possibility of human
germline modifications that increase lifespan).
206. Id. at 21 (discussing how the concept of “normality” might change over time).
207. Patti Neighmond, Women Can Freeze Their Eggs For the Future, But At a
Cost, NAT’L PUB. RADIO (Oct. 16, 2014), https://www.npr.org/sections/health-
shots/2014/10/16/356727823/freezing-a-womans-eggs-can-be-emotionally-and
-financially-costly.
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might prefer to use the gametes and embryos they have, rather than undergo
additional rounds of intrusive procedures like egg extraction, even if they
could produce additional gametes without difficulty.208 Thus, once doctors
begin editing embryos to limit the risk of serious diseases, they might also
consider manipulating or altering other genes (such as the genes that influ-
ence height or athletic performance).209
All of this assumes that CRISPR technology proves safe and effective
and that increasing genomic knowledges makes the interventions more pre-
dictable. Once that occurs, the desire to use CRISPR to assist patients who
could otherwise not reproduce could become substantial. An industry organ-
ized to increase the effectiveness of fertility treatments, by encouraging fer-
tility tourism if necessary, raises the question of whether a dividing line
between acceptable and unacceptable uses of CRISPR can be enforced. That,
in turn, requires considering the role of CRISPR in preventing serious
diseases.
C. CRISPR and the Prevention of Disease
The least controversial part of CRISPR would be its use to prevent a
disease or the transmission of disease-causing genes to subsequent genera-
tions. Yet, germline genetic editing to prevent the transmission of diseases,
unlike such editing to facilitate fertility treatments, is much less likely to
become a routine part of reproductive medicine.210 There are just too many
alternatives for most couples carrying genes they do not wish to transmit to
their offspring.211
At one time, many individuals knew that members of their families were
at increased risk for diseases like sickle cell disease anemia but did not nec-
essarily have many ways to address the possibility of transmission. Today,
they do. If individuals carry a single copy of the gene associated with such
208. See Rachel Gurevich, How Much Does IVF Really Cost?, VERYWELLFAMILY,
https://www.verywellfamily.com/how-much-does-ivf-cost-1960212 (last vis-
ited Mar. 8, 2020) (indicating the price of IVF); In Vitro Fertilization (IVF),
MAYO CLINIC, https://www.mayoclinic.org/tests-procedures/in-vitro-fertiliza-
tion/about/pac-20384716?page=0&citems=10 (last visited Mar. 8, 2020) (indi-
cating that IVF is invasive); but cf. The Egg Retrieval Process, EXTEND
FERTILITY, https://extendfertility.com/services/egg-freezing/the-egg-retrieval/
(last visited Mar. 8, 2020) (indicating that IVF is only minimally invasive).
209. Greely, supra note 22, at 262 (noting the advantages for competitive skiers of
alleles that produce high levels of hemoglobin).
210. See Macintosh, supra note 8, at 276 (explaining the level of support for this
technology amongst polled citizens and how governments across the world
continue to ban germline genetic editing to prevent the transmission of
diseases).
211. See id. at 274.
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autosomal recessive diseases,212 they would be carriers, but they would not
ordinarily suffer from the disease themselves.213 If, on the other hand, both
mother and father passed on copies of the gene to their offspring, the off-
spring would experience the disease.214 Couples who know that they are car-
riers of the gene are accordingly eager not to bear children who would inherit
two copies of the gene. Similarly, adults who have inherited the gene for
Huntington’s disease from a single parent are likely to develop the disease
later in life.215 If they are to have children, they may wish to ensure that they
do not pass on the autosomal dominant gene to their children. In this case, it
does not matter whether the other parent can transmit the gene or not; receiv-
ing a single copy from one parent is enough to cause the disease.216 In both of
these cases, however, PGD together with IVF is ordinarily enough to ensure
that the parents do not pass on the disease to their children.217 These parents
are not necessarily infertile in any way. They may be able to produce large
numbers of embryos, and fertility specialists can chose the embryos to im-
plant that do not pass on a disease causing gene.218 For many couples, this is
sufficient to allow them to bear healthy children, and indeed groups like the
Ashkenazi Jewish communities that have embraced such techniques have
seen a dramatic drop in the incidence of hereditary diseases such as Tay
Sachs without use of genome editing.219
Genetic screening mechanisms such as PGD cannot eliminate the trans-
mission of such diseases entirely, however. For example, suppose a prospec-
tive parent has inherited two copies of the Huntington’s gene, one from each
parent. All of the individual’s gametes will contain the Huntington’s gene
and, therefore, absent germline editing, so will all of the individual’s chil-
dren, even if the second parent does not have the gene.220 Similarly, with a
recessive gene such as the one for sickle cell anemia, it is possible that two
people who each inherited two copies of the gene may still wish to have
children. However, if each parent has two copies of the sickle cell gene, then
all the genes they pass on to their children will also have the gene.221 In
addition, in some cases, such as the risk of HIV transmission, gene editing
212. MACINTOSH, supra note 27, at 14.
213. Id.
214. Id.
215. Id. at 13.
216. Id.
217. Id.
218. MACINTOSH, supra note 27, at 12.
219. See Nancy M.P. King, Human Gene-Editing Research: Is the Future Here
Yet?, 97 N.C. L. REV. 1051, 1073 (2019).
220. MACINTOSH, supra note 27, at 13–14 (indicating that editing gametes may be
more effective than editing embryos).
221. Id. at 14.
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cannot eliminate the disease itself, but the addition of new genes might con-
fer immunity.222 In each of these cases, gene editing would be a way to pre-
vent transmission to the developing fetus in circumstances where genetic
screening could not do so.223
In dealing with genetic diseases, however, it is also possible that doctors
could edit the genes after the children are born, rather than before conception
or implantation. In many cases, somatic editing would be preferable.224 Ordi-
narily, in a child or adult, as opposed to embryo, it would be easier to target
particular tissues, and avoid unplanned changes.225 In addition, if off-target
changes did occur, they would not affect embryonic or fetal development,
which might be particularly damaging, and they would not be passed on to
offspring.226 On the other hand, embryo or gamete editing would be prefera-
ble if the troubling conditions occurred early enough that by the time of the
child’s birth, critical damage is already likely to have occurred, or the child’s
development is likely to have been adversely affected.227 In addition, some
diseases may already be imbedded in a large percentage of the body’s cells
by the time of birth, making it much harder to use somatic cell editing to
eliminate the effects.228
This means there are cases where human germline modification in ga-
metes or embryos might be a valuable way of preventing the transmission of
potentially devastating diseases. Cases like this, where germline editing is the
best or only way of accomplishing such a result, however, are likely to be
rare. First, most of these diseases are rare to begin with.229 Second, cases
where PGD cannot be used to screen gametes or embryos, but germline edit-
222. This is what Dr. He attempted to accomplish. See id. at 15–16 (noting the
tradeoffs involved in this type of genetic editing).
223. See id. at 16.
224. See Greely, supra note 22, at 258.
225. Id. at 260.
226. Id. at 261.
227. Id.
228. Id.
229. See Genetics Home Reference, What Are Genome Editing and CRISPR-Cas9?,
NAT’L LIBR. MED. (Mar. 31, 2020), https://ghr.nlm.nih.gov/primer/ge-
nomicresearch/genomeediting (listing relevant diseases, including cystic fibro-
sis, hemophilia, and sickle cell disease); Ann Pietrangelo, Cystic Fibrosis by
the Numbers: Facts, Statistics, and You, HEALTHLINE, https://www.healthline.
com/health/cystic-fibrosis-facts (last updated Nov. 26, 2019) (“Cystic fibrosis
is an uncommon genetic disorder.”); Hemophilia, CLEVELAND CLINIC, https://
my.clevelandclinic.org/health/diseases/14083-hemophilia (last reviewed Jan.
20, 2020) (“Hemophilia is a rare, inherited bleeding disorder.”); Sickle Cell
Disease, NAT’L ORG. RARE DISORDERS, https://rarediseases.org/rare-diseases/
sickle-cell-disease/ (last visited Apr. 1, 2020) (“Sickle cell disease (SCD) is a
rare blood disorder . . . .”).
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ing is appropriate will be rarer still.230 Third, parents who have two copies of
many of these genes will have the disease and many may not be well enough
to bear or raise children.231 Finally, in some of these cases, other remedies,
such as somatic cell editing will be preferable.232 This leaves a small commu-
nity who may have an intense interest in this technology, but few prospects
for scaling up its implementation to the point where it becomes routine.
Therefore, to the extent it makes sense to encourage the development of
CRISPR as a disease prevention technology, it might make more sense to tie
its development to the specialists developing disease specific therapies, in-
cluding somatic genome editing. Patient groups wishing to manage reproduc-
tion would then want a choice of options that may include testing prospective
partners, access to PGD and IVF, and genetic modification as a last resort. In
this context, germline alterations should be thought of as part of disease treat-
ment and management. Insurance companies in turn may want to extend cov-
erage to reproductive techniques to avoid incurring the costs associated with
covering children at greater risk for the disease. Further, specialists who
work with these patient groups should be trained to counsel their patients on
reproductive access. Development of gene editing technology should take
place within the same framework as other treatments associated with manag-
ing diseases associated with genetic inheritance.
If CRISPR and other forms of germline editing are restricted to these
groups, however, either legally or practically, then the major issue will be
funding. A private globalized industry is unlikely to develop simply to help
eliminate the transmission of these genes even though many ethicists would
ideally like to see CRISPR use, if it is permitted at all, limited to these popu-
lations.233 Indeed, that may be likely unless CRISPR is tied to the ability to
solve fertility issues that affect a broader population than simply those with
genetic diseases. In short, use of CRISPR in the reproductive context to assist
in disease prevention is likely to remain rare and relatively easy to regulate.
230. Indeed, the incidence of Tay-Sachs disease in the Jewish population in the
United States has fallen by more than ninety percent since the seventies. See Ira
Stoll, How the Jews Nearly Wiped Out Tay-Sachs, JEWISH TELEGRAPHIC
AGENCY (Aug. 11, 2017), https://www.jta.org/2017/08/11/united-states/how-
the-jews-nearly-wiped-out-tay-sachs.
231. See Genetics Home Reference, supra note 229; Katie Willard Virant, Parenting
with Chronic Illness, PSYCHOL. TODAY (Jan. 14, 2019), https://
www.psychologytoday.com/us/blog/chronically-me/201901/parenting-chronic-
illness (explaining the challenges of parenting with chronic illness).
232. Greely, supra note 22, at 260 (describing for example, somatic cell treatments
for sickle cell anemia).
233. Ed Yong, The Designer Baby Era Is Not upon Us, ATLANTIC (Aug. 2, 2017),
https://www.theatlantic.com/science/archive/2017/08/us-scientists-edit-human-
embryos-with-crisprand-thats-okay/535668/.
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IV. CONCLUSION
The attention focused on the prospect of germline genomic modification
is, at this point, largely unwarranted. Dr. He’s experimentation with CRISPR
in China was premature and deserves international condemnation. The more
important focus should be on the development of CRISPR to effect somatic
cell alterations that treat existing diseases. In looking to the future, the use of
CRISPR to effect germline changes to eliminate the transmission of disease-
causing genes to infants, while not ready for implementation right now, is
likely to be a development that still has limited impact outside of those fami-
lies plagued with hereditary diseases. Instead, the potentially far-reaching im-
pact of CRISPR depends on whether it becomes a more important part of the
fertility industry, that has been establishing globalized platforms that match
patients with new technologies. Should CRISPR become part of efforts to
increase the efficacy of reproduction, to increase the numbers of viable ga-
metes, or to enhance the health of the resulting children, it will have much
more far reaching implications than if its use is limited to preventing disease
transmission. In that case, the questions are not so much about CRISPR it-
self, but about the channeling and development of reproductive medicine on
a global basis.
